Nataly Tarasenko Felsenstein Medical Research Center Biography Publications Institution JoVE Articles Nataly Tarasenko has not added a biography. If you are Nataly Tarasenko and would like to personalize this page please email our Author Liaison for assistance. Publications Palbociclib in Combination with Sunitinib Exerts a Synergistic Anti-cancer Effect in Patient-derived Xenograft Models of Various Human Cancers Types Cancer Letters. Jun, 2022 | Pubmed ID: 35358627 Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer Pharmaceuticals (Basel, Switzerland). Nov, 2021 | Pubmed ID: 34959644 The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model International Journal of Molecular Sciences. Feb, 2019 | Pubmed ID: 30736437 Comparison of the Anticancer Properties of a Novel Valproic Acid Prodrug to Leading Histone Deacetylase Inhibitors Journal of Cellular Biochemistry. Apr, 2018 | Pubmed ID: 29135083 AN-7, a Butyric Acid Prodrug, Sensitizes Cutaneous T-cell Lymphoma Cell Lines to Doxorubicin Via Inhibition of DNA Double Strand Breaks Repair Investigational New Drugs. Feb, 2018 | Pubmed ID: 28884410 Effects of Histone Deacetylase Inhibitory Prodrugs on Epigenetic Changes and DNA Damage Response in Tumor and Heart of Glioblastoma Xenograft Investigational New Drugs. Aug, 2017 | Pubmed ID: 28315153 Bi-functional Prodrugs of 5-aminolevulinic Acid and Butyric Acid Increase Erythropoiesis in Anemic Mice in an Erythropoietin-independent Manner European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. Aug, 2016 | Pubmed ID: 27283485 The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin PloS One. 2016 | Pubmed ID: 26752418 A Novel Valproic Acid Prodrug As an Anticancer Agent That Enhances Doxorubicin Anticancer Activity and Protects Normal Cells Against Its Toxicity in Vitro and in Vivo Biochemical Pharmacology. Mar, 2014 | Pubmed ID: 24463168 Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor PloS One. 2012 | Pubmed ID: 22384017 The Histone Deacetylase Inhibitor Butyroyloxymethyl Diethylphosphate (AN-7) Protects Normal Cells Against Toxicity of Anticancer Agents While Augmenting Their Anticancer Activity Investigational New Drugs. Feb, 2012 | Pubmed ID: 20862515 Gamma-aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity Journal of Medicinal Chemistry. May, 2009 | Pubmed ID: 19378992 Histone Deacetylase Inhibitors: the Anticancer, Antimetastatic and Antiangiogenic Activities of AN-7 Are Superior to Those of the Clinically Tested AN-9 (Pivanex) Clinical & Experimental Metastasis. 2008 | Pubmed ID: 18506586 The Selectivty and Anti-metastatic Activity of Oral Bioavailable Butyric Acid Prodrugs Investigational New Drugs. Sep, 2006 | Pubmed ID: 16502348 Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs Neta Moskovits1,2, Ella Itzhaki1,2, Nataly Tarasenko1,2, Eva Chausky1,2, Avital Bareket-Samish3, Aleksandr Kaufman1,2, Raisa Meerson1,2, Salomon M. Stemmer1,2,4 1Felsenstein Medical Research Center, 2Davidoff Center, Rabin Medical Center, 3BioInsight Ltd., 4Sackler Faculty of Medicine, Tel Aviv University JoVE 64564 Cancer Research
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs Neta Moskovits1,2, Ella Itzhaki1,2, Nataly Tarasenko1,2, Eva Chausky1,2, Avital Bareket-Samish3, Aleksandr Kaufman1,2, Raisa Meerson1,2, Salomon M. Stemmer1,2,4 1Felsenstein Medical Research Center, 2Davidoff Center, Rabin Medical Center, 3BioInsight Ltd., 4Sackler Faculty of Medicine, Tel Aviv University JoVE 64564 Cancer Research
